date:May 09, 2012
Medication Guide is also being updated to inform patients about this risk. Healthcare professionals should consider both the potential benefit of Revlimid and the risk of second primary malignancies when deciding to treat patients with this drug, and monitor patients for this risk.
[Posted 04/08/2011]
AUDIENCE:Hematology, Oncology
ISSUE:FDA is informing the public that we are aware of results from clinical trials conducted inside and outside the UnitedStates that found that patients treated with